Preclinical results for M‑3554, an antibody‑drug conjugate (ADC) targeting GD2 with a β‑glucuronide linker and exatecan payload, demonstrate potent antitumor activity in neuroblastoma and soft‑tissue sarcoma xenografts and engineered safety features intended to reduce anti‑GD2 pain. Developers reported tumor regressions in multiple models and argue the linker–payload chemistry improves therapeutic window. The disclosure frames M‑3554 as an ADC optimized for solid tumor indications expressing GD2; key next steps include toxicology, dose‑optimization, and clinical translation to determine whether preclinical efficacy and reduced neuropathic pain signals translate to patients.